Featured Research

from universities, journals, and other organizations

Approach To Treat Bone Loss Might Increase Bone Cancer Risk

Date:
April 1, 2009
Source:
Journal of Clinical Investigation
Summary:
One approach being considered as a new way to treat osteoporosis is the development of molecules that block the action of proteins that inhibit the Wnt signaling pathway. However, dysregulated Wnt signaling is associated with several cancers.

One approach being considered as a new way to treat osteoporosis is the development of molecules that block the action of proteins that inhibit the Wnt signaling pathway. However, dysregulated Wnt signaling is associated with several cancers.

Further, David Thomas and colleagues, at Peter MacCallum Cancer Centre, Australia, have now shown that the gene responsible for making the Wnt signaling pathway inhibitor WIF1 is silenced in human osteosarcomas (the most common form of bone cancer) and that its absence in mice accelerated the development of radiation-induced osteosarcomas.

The authors therefore conclude that targeting Wnt signaling pathway inhibitors is likely to increase susceptibility to osteosarcomas.

Thus, both the authors and, in an accompany commentary, Greg Enders, at Fox Chase Cancer Center, Philadelphia, note that caution is needed before this approach is used in clinical trials to treat patients with bone loss disorders such as osteoporosis.

The research is published in the March 23, 2009, issue of the Journal of Clinical Investigation.



Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal References:

  1. Kansara et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI37175
  2. Greg H. Enders. Wnt therapy for bone loss: golden goose or Trojan horse? Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI38973

Cite This Page:

Journal of Clinical Investigation. "Approach To Treat Bone Loss Might Increase Bone Cancer Risk." ScienceDaily. ScienceDaily, 1 April 2009. <www.sciencedaily.com/releases/2009/03/090324213023.htm>.
Journal of Clinical Investigation. (2009, April 1). Approach To Treat Bone Loss Might Increase Bone Cancer Risk. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/03/090324213023.htm
Journal of Clinical Investigation. "Approach To Treat Bone Loss Might Increase Bone Cancer Risk." ScienceDaily. www.sciencedaily.com/releases/2009/03/090324213023.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins